Background: Onychomycosis is a chronic fungal infection of the nail, characterized by nail discoloration, subungual hyperkeratosis, and onycholysis. The involved pathogens are dermatophytes, yeasts (Candida), and non-dermatophyte molds.Dermatophytes such as Trichophyton rubrum and Trichophyton mentagrophytes are the most common agents of onychomycosis, with higher prevalence of the infection in toenails than in fingernails. Candida albicans affects almost exclusively the fingernails, and accounts for 10% of toenail onychomycosis. Itraconazole is a broad-spectrum antifungal drug which is active against a range of fungal species, including yeasts, dermatophytes and some non-dermatophyte molds, is a more convenient antifungal drug for different types of onychomycosis. Itraconazole is licensed at a dose of 200 mg daily for 12 weeks continuously or intermittently as pulse therapy at a dose of 400 mg daily for 1 week per month for 2-3 pulses in fingernail infections and 3-4 pulses for toenail disease.Although itraconazole pulse therapy has proven to be an effective and acceptable onychomycosis therapies, the complete cure rate remains unsatisfactory, indicating that 3-4 cycles of pulse therapy for toenail onychomycosis might be inadequate for severe cases of onychomycosis. Thus, the development of a more effective and suitable therapeutic regimen to improve the complete cure rate is necessary.